Stem cell biology

SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells

Mariusz Z. Ratajczak 1,2 - Magda Kucia1,2

Abstract

The scientific community faces an unexpected and urgent challenge related to the SARS-CoV-2 pandemic and is investigating the role of receptors involved in entry of this virus into cells as well as pathomechanisms leading to a cytokine “storm,” which in many cases ends in severe acute respiratory syndrome, fulminant myocarditis and kidney injury. An important question is if it may also damage hematopoietic stem progenitor cells?

Despite the massive virulence of SARS-CoV-2, we are in a much better position to investigate this virus than HIV 40 years ago, when the first cases of AIDS were reported. At the beginning of the HIV era it was still a conundrum how the virus could infect cells. It took some time to identify HIV co-receptors, and much more time was needed to develop antiretroviral drugs, and some of these could perhaps find therapeutic application today in SARS-CoV-2 patients before a safe and effective vaccine is available. To the benefit of mankind, more antiviral tools are available in the 21st century, and thanks to the internet it is much easier to exchange information in the fight with this invisible enemy.

Recently, Leukemia published a review on the role of the Nlrp3 inflammasome in normal and malignant hematopoiesis [1]. However, life (and nature) has unexpected twists and turns, and evidence has accumulated that the Nlrp3 inflammasome may be the culprit in certain complications of SARS-CoV-2 infection, which may affect several tissues and organs as well as potentially hematopoiesis. Specifically, there is evidence that the SARS-CoV-2 virus entry receptor (angiotensin-converting enzyme 2; ACE2) and receptor for angiotensin II (AT1) are expressed and functional on the surface of hematopoietic stem/progenitor cells (HSPCs) [2, 3]. Therefore, SARS-CoV-2 may on one hand directly infect pool of HSPCs, and on other pathological activation of Nlrp3 inflammasome may lead to cytokine storm and pyroptosis of these cells.

We already know that SARS-CoV-2 utilizes a spike protein (S) for attachment and entry into cells, which binds to a cell-surface expressed ACE2. Moreover, as reported recently, S protein must be primed by transmembrane protease serine 2 (TMPRSS2) to facilitate interaction with ACE2 and the subsequent fusion of viral and cellular membranes [4]. Therefore, some potential targets for future molecular interventions are already known.

Interestingly, while HIV sneaks into cells by employing entry receptors that are abundantly expressed on the surface of immune and hematopoietic cells (CD4, CXCR4, and CCR5), SARS-CoV-2 dysregulates the function of receptors involved in the regulation of blood pressure, fluid and electrolyte balance, as well as systemic vascular resistance [5]. Specifically, because SARS-CoV-2 utilizes the ACE2 receptor for cell entry, which becomes internalized after virus binding, it triggers hyperactivation of the renin–angiotensin–aldosterone system. To explain this complication, ACE2 is an enzyme that converts angiotensin I to angiotensin 1-9 and angiotensin II to angiotensin 1–7, and a lack of ACE2 leads to elevated levels of both of these peptides, which activate the angiotensin AT1 and AT2
receptors on the surfaces of endothelial, lung epithelium, intestine epithelium, kidney cells and what is important for us hematologists also on hematolymphopoietic cells [2, 3, 6]. Moreover, a lack of ACE2 impairs processing of angiotensin II to seven aminoacid peptides, angiotensin 1-7, which, by interacting with the MAS receptor, counteract the unwanted vasopressive and pro-fibrotic effects of the AT1 receptor [5].

Importantly, while considering the pathogenesis leading to initiation of a cytokine “storm” in the development of SARS-CoV-2 pathologies, one has to keep in mind the presence of a powerful proinflammatory system, the Nlrp3 inflamasome, which is expressed in many cell types, including innate immunity, endothelial, hematopoietic, lung epithelial, kidney, and cardiac cells [1, 7]. In fact, evidence indicates that the Nlrp3 inflamasome becomes activated in these cells in response to angiotensin II stimulation [8–11]. Whether interaction of the SARS-CoV-2 spike protein with ACE2 can do the same is currently being investigated in our laboratory. What is also important, our group demonstrated expression of the Nlrp3 inflamasome in hematopoietic stem/progenitor cells (HSPCs) [1] and what is also known ACE2 and AT1 receptors are expressed on HSPCs [2, 3]. Thus, determining the effect of SARS-CoV-2 on hematopoiesis requires careful investigation as these cells could be directly infected by virus and in addition a high level of angiotensin II could hyperactivate Nlrp3 inflamasome in these cells leading to cell death by pyroptosis. To support this angiotensin II mediated pyroptosis due to hyperactivation of Nlrp3 inflamasome has been already reported to occur in lung epithelium, kidney cells and cardiomyocytes [9–11].

It is known that activation of the Nlrp3 inflamasome triggers an immune response via intracellular caspase 1, which leads to (i) release of potent proinflammatory cytokines, such as interleukin-1β and interleukin 18, and (ii) by creating gasdermin D (GSDMD) pore channels in cell membranes, mediating the release of several biologically active danger-associated molecular pattern molecules (DAMPs). This initiates a sequence of events leading to amplification of the innate immune system response and activation of its major humoral arm, the complement cascade (ComC) [1]. In addition to DAMPs, the ComC, as recently reported, is directly activated by mannan-binding lectin (MBL), which binds to SARS-CoV-2 proteins [12]. Importantly, activation of the ComC via the MBL–MASP-2 protease complex leads, in parallel, to activation of the coagulation cascade (CoaC), and in patients infected with SARS-CoV-2, activation of coagulation correlates with a worse prognosis [13]. This explains why inhibition of the ComC or CoaC is considered to be a potential treatment option.

Considering the potential leading role of the Nlrp3 inflamasome hyperactivation in the pathogenesis of SARS-CoV-2 caused multi organ failure, we have to consider three scenarios for how this intracellular protein complex could become activated and finally leads to cytokine storm and cell death by pyroptosis (Fig. 1). First, it is possible that the SARS-CoV-2 spike protein (S), after binding to cell surface-expressed ACE2, directly triggers its enzymatic activation and downstream signaling. ACE2 has, in fact, been reported to be a signaling receptor. Thus, infection of cells could result in activation of Nlrp3 inflamasome and pyroptosis. Second, also as previously reported, after binding to the AT1 receptor, angiotensin II is an important activator of the Nlrp3 inflamasome in lung, kidney cells, and cardiomyocytes. This could be a common mechanism in other cell types including hematopoietic cells. Third, recognition and interaction of the ComC with SARS-CoV-2 releases several potent cleavage fragments, such as the C3a and C5a anaphylatoxins as well as the C5bC9 membrane attack complex, which may also directly trigger activation of the Nlrp3 inflamasome. Several types of Nlrp3 inflamasome-positive cells, including innate immunity and lympho/hematopoietic cells express C3a- and C5α-binding receptors.

We postulate that the main problem with Nlrp3 inflamasome in pathogenesis of SARS-CoV-2 infection is its overactivation, leading to perturbation of mitochondrial function, the release of DAMPs, and cell death by pyroptosis [1, 7, 9–11]. This all raises the important question of whether Nlrp3 inflamasome inhibitors (e.g., the small molecule MCC950), similarly to other compounds proposed to affect SARS-CoV-2 binding to the cells and to inhibit intracellular virus amplification, and compounds that modulate activity of the innate immune system (e.g., ComC inhibitors) will find therapeutic application. There is also a potential role of mesenchymal stromal cells as potential modulators of the inflammatory response in the lungs and in other tissues.

An important question is whether SARS-CoV-2 infection affects stem cells including HSPCs. As mentioned above it is known that SARS-CoV-2 entry receptors are expressed on the surfaces of HSPCs, on endothelial progenitor cells, and even on more developmentally early common progenitors for the hematopoietic and endothelial lineages (manuscript in preparation). Moreover, since, as we already reported, HSPCs express Nlrp3 inflamasome components, it would be important to observe the long-term effects of SARS-CoV-2 infection on the hematopoietic stem cell compartment. In addition, virus could also affect stem cells in other organs, including lungs, myocardium, or small intestine. The complications of viral infection could be direct, involving specific entry receptors leading to elimination of infected cells, or indirect, involving activation of...
systemic immune response pathways. It is known that during the first days of infection innate immunity is a main responder against SARS-CoV-2 until acquired immunity responds with production of antibodies.

In conclusion, all pathological pathways depicted in Fig. 1 may lead to Nlrp3 inflammasome overactivation, implying that the virus not only triggers cytokine storm but most likely also affects the stem cell compartment in various organs and we may identify soon some remote consequences of SARS-CoV-2 infection [14, 15]. One of important questions remains if inhibition of overactivated Nlrp3 inflammasome could find clinical application?

However, to remain optimistic, let’s hope that the current armamentarium of scientific tools and the ability to rapidly communicate between different research groups will lead to dethroning of this treacherous virus, with its stolen crown (corona). We hope to soon banish this usurper from the realm along with its all of its relatives.

Acknowledgements This work was supported by NIH grants 2R01 DK074720, Stella and Henry Hoenig Endowment, and the Polish National Center OPUS grants UMO-2018/29/B/NZ4/01470 to MZR and 2016/21/B/NZ4/00201 to MK.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Ratajczak MZ, Bujko K, Cymer M, Thapa A, Adamiak M, Ratajczak J, et al. The Nlrp3 inflammasome as a “rising star” in studies of normal and malignant hematopoiesis. Leukemia. 2020. https://doi.org/10.1038/s41375-020-0827-8.

2. Park TS, Zambidis ET. A role for the renin-angiotensin system in hematopoiesis. Haematologica. 2009;94:745–7. https://doi.org/10.3324/haematol.2009.006965.

3. Zambidis ET, Park TS, Yu W, Tam A, Levine M, Yuan X, et al. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood. 2008;112:3601–14. https://doi.org/10.1182/blood-2008-03-144766.

4. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.e8. https://doi.org/10.1016/j.cell.2020.02.052.

5. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653–9. https://doi.org/10.1056/NEJMoa2005760.

6. Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020. https://doi.org/10.1038/s41423-020-0424-9.

7. Place DE, Kaneganti TD. Recent advances in inflammasome biology. Curr Opin Immunol. 2018;50:32–38.

8. Rodgers KI, Xiong S, DiZerega GS. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharm. 2003;51:97–106.

9. Zhao M, Bai M, Ding G, Zhang Y, Huang S, Jia Z, et al. Angiotensin II stimulates the NLRP3 inflammasome to induce podocyte injury and mitochondrial dysfunction. Kidney Dis. 2018;4:83–94. https://doi.org/10.1159/000488242.

10. Sun NN, Yu CH, Pan MX, Zhang Y, Zheng BJ, Yang QJ, et al. Mir-21 mediates the inhibitory effect of Ang (1-7) on AngII-induced NLRP3 inflammasome activation by targeting Spry1 in lung fibroblasts. Sci Rep. 2017;7:14369. https://doi.org/10.1038/s41598-017-13305-3.

11. Pinar AA, Scott TE, Huuskes BM, Tapia Cáceres FE, Kemp-Harper BK, et al. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharm Ther. 2020;209:107511. https://doi.org/10.1016/j.pharmthera.2020.107511.

12. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, HARP J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020. pii: S1931-5244(20)30070-0. https://doi.org/10.1016/j.trsl.2020.04.007.

13. Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. Thromb Haemost. 2020. https://doi.org/10.1055/s-0040-1710317.

14. von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F; EHA Infectious Disease Scientific Working Group, Hirsch HH. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020. https://doi.org/10.1038/s41375-020-0836-7.

15. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W et al. COVID-19 in persons with haematological cancers. Leukemia. 2020. https://doi.org/10.1038/s41375-020-0836-7.